A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Epix Pharmaceuticals, Inc.
• Treatments: Naluzotan

Criteria

Key Inclusion Criteria:

• Diagnosis of major depressive disorder

Key Exclusion Criteria:

• Females who are pregnant or nursing

• Electroconvulsive therapy within previous year

• Type 1 diabetes or uncontrolled type 2 diabetes

• HIV, Hepatitis B or Hepatitis C

• Use of illegal drugs, history of drug abuse, and/or alcohol dependence

• Clinically significant abnormal lab results

Other protocol-defined eligibility criteria may apply.